Skip to main content
AIBT
OTC Life Sciences

AIBOTICS Reports Zero Revenue, Worsening Liquidity, and Massive Dilution in Q1

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0.001
Mkt Cap
$510.926K
52W Low
$0.001
52W High
$0.024
Market data snapshot near publication time

Summary

Aibotics, Inc. reported zero revenue and a worsening financial position in Q1 2026, alongside significant share dilution and reiterated 'going concern' and internal control warnings.


Key Events

  • Zero Revenue Reported

    The company generated no revenue for the three months ended March 31, 2026, down from $2,183 in the same period last year.

  • Worsening Liquidity and Going Concern

    The working capital deficit increased to $4.72 million as of March 31, 2026, and the company reiterated its 'going concern' warning due to recurring losses and negative cash flows.

  • Significant Share Dilution

    Aibotics issued approximately 52.4 million common shares for $98.2 thousand in Q1 2026, and an additional 142.5 million shares for $112.9 thousand in subsequent events, representing substantial dilution.

  • Multiple Debt Defaults

    Several convertible notes payable, including those from Lender G (formerly Lender A), Lender B, and Lender E, are in default, with default interest accruing at 20%.


Analysis

Aibotics, Inc. reported zero revenue for the first quarter of 2026, a significant decline from $2,183 in the prior year, highlighting severe operational challenges. The company's financial position deteriorated further with a worsening working capital deficit of $4.72 million and increased cash burn from operations. The filing reiterates a 'going concern' warning and material weaknesses in internal controls, consistent with previous disclosures. To manage liquidity, the company engaged in highly dilutive financing activities, issuing approximately 52.4 million shares for $98.2 thousand in Q1 2026, and an additional 142.5 million shares for $112.9 thousand in subsequent events, representing a substantial portion of its market capitalization. Multiple convertible notes are in default, and a new equity incentive plan for 500 million shares signals potential for further significant dilution.

At the time of this filing, AIBT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $510.9K. The 52-week trading range was $0.00 to $0.02. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIBT - Latest Insights

AIBT
Jun 09, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.0009
Real-time Price: $0.0009 info
Change: $0 (0%) info
Market Cap: $510.926K info
AIBT
Jun 08, 2026, 7:12 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0009
Real-time Price: $0.0009 info
Change: $0 (0%) info
Market Cap: $510.926K info
AIBT
May 19, 2026, 9:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.0007
Real-time Price: $0.0009 info
Change: +$0.0002 (+29%) info
Market Cap: $510.926K info
AIBT
Apr 30, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.0011
Real-time Price: $0.0009 info
Change: -$0.0002 (-18%) info
Market Cap: $510.926K info
AIBT
Apr 15, 2026, 4:20 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.0011
Real-time Price: $0.0009 info
Change: -$0.0002 (-18%) info
Market Cap: $510.926K info